Search Results for: ankit

By Ankit Mahadevia, former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC The right leaders in the right structure can power companies to great things. The general consensus is that all companies need a

By Ankit Mahadevia, Chairman of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Nobody stays in a particular role forever. While change at the senior level can be disruptive, it doesn’t have to be. Teams and

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC This time a quarter ago organizations large and small were in the thick of the “to hybrid or not to hybrid” debate. Each

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC As I ride the Amtrak towards New York City for a series of meetings on Park Avenue with bankers/analysts, face-to-face (F2F) meetings are

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotwitter is great for healthy debates.  The most recent has been on the merits of the hybrid vs.an in-person model.  John Maraganore’s excellent

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotechnology, especially of late, requires us to prevail over adversity to deliver for patients.  Spero, dedicated to new solutions for patients with infections,

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has brought unique challenges for growing companies.  Capital markets, shifting regulatory winds and other emergent forces are driving tough decisions on programs,

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC For anyone that’s part of a fast paced, growing organization, resilience is the key to thriving.  It supports our audacity, ability to tune

By Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Recently, Spero announced the filing of its first ever New Drug Application, for our medicine tebipenem Hbr.  Interestingly, as we approached

By Ankit Mahadevia, CEO and Founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. The opportunity for each member of a NewCo to take on multiple responsibilities selects early for people ready to help a

The role of the core in making an organization great and how we do right by them By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Small organizations are amazing for the

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this fall, we prepared to report Phase III data for tebipenem HBr, our oral medication that, if approved, could help 2.7M patients

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. “Hey, you know, breakdowns come. And breakdowns go. So what are you going to do about it? That’s what I’d like to know – Gumboots In an

This blog was written by Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC. In an environment where senior leaders are tasked with defining agile strategies in uncertain times, there are many perspectives

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  If CEOs have empowered their teams effectively, they have three roles during times of rapid change: Motivator in chief

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  One of the joys of building a company is that meeting one’s milestones routinely places us in positions that

This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  At Spero we are privileged to be enrolling our pivotal study for SPR994, our oral antibiotic with

This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Over my experience building several therapeutics companies, I’ve sometimes observed a Field of Dreams approach to therapeutics:

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC.   The biotech twittersphere recently engaged in very thoughtful debate (resulting in a great piece by

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much has been said about who and when to hire in this blog (here and here for example), but

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  Relative to a decade ago, those of us that have spent time finding new ways to outsmart drug-resistant bacteria

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Startup life can be grueling.  It’s an especially gratifying feeling when your data and your investors signal that it’s

Jumping into a first-time CEO role in an emerging biotech is a daunting but exciting opportunity – both for the newly-minted chief executive and their Board of Directors. A great hire can be positively catalytic to a startup; and, sadly,

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Infectious disease has had an ebb and flow relationship with our general awareness; epidemics such as Zika, Ebola, and

This blog was written by Ankit Mahadevia, CEO at Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In my experience, looking to the outside world for new pipeline ideas isn’t just the realm of larger companies.   The

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. After many months (or years) of grinding, your science seems to be working, the market is responding to your story,

This blog was written by Ankit Mahadevia, co-founder of Spero, Synlogic, and Rodin Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The concept of “getting s#it done” is central to our lives as entrepreneurs. With time and capital

This afternoon Nature Biotechnology published its annual review of the “some of the best that academic research had to offer the startup world in 2014.” The article, in the March 2015 issue, covers the editors’ selections of the top startups

This blog was written by Jeff Hatfield, CEO of Vitae Pharmaceuticals, as part of the “From the Trenches” feature of LifeSciVC. Over the past two weeks in LifeSciVC, I read with great interest and appreciation the blogs of two friends of

This blog was written by Ankit Mahadevia, Atlas EIR and c0-founder of Spero and Rodin Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. As startup folks we are great at keeping our heads down and looking ahead; this

Today Synlogic announced that the Bill & Melinda Gates Foundation joined the Series A financing to help power up its platform around developing therapeutic microbes (here).  Combining compelling elements of two exciting fields – engineering organisms with synthetic biology and

This blog was written by Ankit Mahadevia, CBO of Rodin Therapeutics and Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. There’s an ebb and flow in our business around interest in specific therapeutic areas; hot TAs such

Three years ago this month I started this LifeSciVC blog experiment and its been more fun and rewarding than I would have expected. As I wrote in my first post, the reasons I started blogging were to add a voice

Seed-led venture creation is our focus at Atlas, and, with the closing of our new fund, 2013 has been a very active year for us.  As part of a year-end reflection, it’s a good opportunity to present a quick sketch

Last week, Atlas Venture closed Fund IX at $265M, as reported this morning by Dan Primack.  We set out to raise $250M, and closed above-target with great support from our existing LP’s and some great new ones.  With this closing,

Like many technologies that move from hot discoveries on the cover of Nature to the practical ugly sausage-making of drug development, RNA-based therapeutics have been widely derided of late.  It seems everyone from Wall Street to Pharma to venture capital